Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xtant Medical Holdings (XTNT) Research & Development (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Research & Development for 13 consecutive years, with $634000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development fell 9.56% to $634000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $2.2 million, a 8.11% decrease, with the full-year FY2024 number at $2.4 million, up 78.52% from a year prior.
  • Research & Development was $634000.0 for Q3 2025 at Xtant Medical Holdings, up from $566000.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $701000.0 in Q3 2024 to a low of $151000.0 in Q4 2021.
  • A 5-year average of $376315.8 and a median of $262000.0 in 2021 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: fell 25.31% in 2023, then soared 253.33% in 2024.
  • Xtant Medical Holdings' Research & Development stood at $151000.0 in 2021, then surged by 53.64% to $232000.0 in 2022, then soared by 112.07% to $492000.0 in 2023, then increased by 6.1% to $522000.0 in 2024, then increased by 21.46% to $634000.0 in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Research & Development are $634000.0 (Q3 2025), $566000.0 (Q2 2025), and $443000.0 (Q1 2025).